Dr. Rapoport Describes Samsca's Mechanism of Action

Video

In Partnership With:

Frederick Alan Rapoport, MD, clinical instructor in the Department of Medicine at NYU Langone Medical Center, describes the mechanism and utility of Samsca (tolvaptan).

Frederick Alan Rapoport, MD, clinical instructor in the Department of Medicine at NYU Langone Medical Center, describes the mechanism and utility of Samsca (tolvaptan).

Samsca is a drug used for the treatment of dilutional hyponatremia, a common manifestation of many cancers, including small cell lung cancer.

Samsca is an intelligent drug, Rapoport says, that blocks the vasopressin receptor in the kidneys. By blocking this receptor, the dilute urine can be excreted rather than reabsorbed as fluid in the body, which causes hyponatremia.

Related Videos
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Akriti Jain, MD
Samer A. Srour, MB ChB, MS